Concepedia

Dominic Labriola

DL

Statistics

Publications

15

Citations

3.3K

H-Index

14

Active since

1983

Affiliations

Madrigal Pharmaceuticals (United States)(Current)

DuPont (United States)

Pinnacle Clinical Research

Wilmington University

Arizona Liver Health

Dominic Labriola is an author at Madrigal Pharmaceuticals (United States) specializing in medicine, public health, and health sciences.

Top concepts

Publications per year

1983–2024

15

Publications

15

A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis

Stephen A. Harrison, Pierre Bédossa, Cynthia D. Guy et al. · New England Journal of Medicine · 2024 · 1.4K citations · Full text

Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in Adults

Schlomo Staszewski, Javier O Morales-Ramirez, Karen T. Tashima et al. · New England Journal of Medicine · 1999 · 1K citations · Full text

Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial

Stephen A. Harrison, Rebecca Taub, Guy Neff et al. · Nature Medicine · 2023 · 348 citations · Full text

Lack of Efficacy of Naltrexone in the Prevention of Alcohol Relapse: Results From a German Multicenter Study

Markus Gastpar, Udo Bonnet, J. Böning et al. · Journal of Clinical Psychopharmacology · 2002 · 129 citations

Conducting Clinical Research During the COVID-19 Pandemic

Thomas R. Fleming, Dominic Labriola, Janet Wittes · JAMA · 2020 · 106 citations

, , +12

1–5 of 15